Literature DB >> 17671883

Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review.

Javier Garduno1, Monali J Bhosle, Rajesh Balkrishnan, Steven R Feldman.   

Abstract

OBJECTIVE: To assess which measures are utilized to quantify lesions, disease severity, and quality of life in the current literature on psoriasis vulgaris.
METHODS: A MEDLINE search was performed with the keyword 'psoriasis' and the following limits 'All Adult: 19+ years', 'published in the last 5 years', 'English', 'Randomized Controlled Trial', and 'Humans'. The 'Methods' section of the individual articles were reviewed for inclusion criteria that described the study participants' state of psoriasis or disease generalization at baseline, methods used to classify or measure psoriasis during the study, the primary and secondary endpoints, and the quality of life measures utilized in each study.
RESULTS: A search resulted in a total of 180 articles, out of which 134 were utilized for the review. The criteria most commonly utilized were 'moderate to severe psoriasis', 'BSA >/=10%', 'mild to moderate psoriasis', and 'severe psoriasis'. PASI was the most commonly used measure to describe the extent of psoriasis. The most common QoL measure used was DLQI, being used in 54.8% of the articles that used some form of QoL measure/s. DISCUSSION: Various measures are being utilized for the same purpose of generalizing disease/lesion severity and determining 'quality of life'.

Entities:  

Mesh:

Year:  2007        PMID: 17671883     DOI: 10.1080/09546630701271807

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  7 in total

1.  Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.

Authors:  Rachel S Klein; Pamela A Morganroth; Victoria P Werth
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

2.  Histopathological findings are associated with the clinical types of psoriasis but not with the corresponding lesional psoriasis severity index.

Authors:  Byung Yoon Kim; Jae Woo Choi; Bo Ri Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2015-02-03       Impact factor: 1.444

3.  Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.

Authors:  A Marchand; A Caille; V Gissot; B Giraudeau; C Lengelle; H Bourgoin; B Largeau; S Leducq; A Maruani
Journal:  Trials       Date:  2022-07-08       Impact factor: 2.728

4.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

5.  Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.

Authors:  J C Cappelleri; A G Bushmakin; J Harness; C Mamolo
Journal:  Qual Life Res       Date:  2013-03-09       Impact factor: 4.147

6.  Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council.

Authors:  Bruce Strober; Peter C M van de Kerkhof; Kristina Callis Duffin; Yves Poulin; Richard B Warren; Claudia de la Cruz; Joelle M van der Walt; Bradley S Stolshek; Mona L Martin; Andre V E de Carvalho
Journal:  Am J Clin Dermatol       Date:  2019-10       Impact factor: 7.403

7.  Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.

Authors:  Sophie Leducq; Agnès Caille; Sébastien Barbarot; Nathalie Bénéton; Didier Bessis; Olivia Boccara; Anne-Claire Bursztejn; Christine Chiaverini; Anne Dompmartin; Catherine Droitcourt; Valérie Gissot; Dominique Goga; Laurent Guibaud; Denis Herbreteau; Anne Le Touze; Christine Léauté-Labrèze; Gérard Lorette; Stéphanie Mallet; Ludovic Martin; Juliette Mazereeuw-Hautier; Alice Phan; Patrice Plantin; Isabelle Quéré; Pierre Vabres; Hélène Bourgoin; Bruno Giraudeau; Annabel Maruani
Journal:  Trials       Date:  2019-12-17       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.